Vanda Pharmaceuticals (VNDA) Reports Q2 Loss, Misses Revenue Estimates

Vanda, which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $52.59 million for the quarter ended June 2025, missing the Zacks Consensus Estimate by 4.38%. This compares to year-ago revenues of $50.47 million. The company has topped consensus revenue estimates three times over the last four quarters. The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commenta ...